Findings

What do systematic reviews say?

4,695 questions · 4,979 findings · 433 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 998 · 20%GRADE not reported 1,140 · 22.9%Very low 1,024 · 20.6%Low 1,029 · 20.7%Moderate 636 · 12.8%High 152 · 3.1%

IPV(3)‐OPV vs IPV(2)‐OPV

Vaccine‐associated paralytic polio (VAPP) cases (Range of · preventing poliomyelitis

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

IPV(3)‐OPV vs IPV(2)‐OPV

Neutralising antibodies · preventing poliomyelitis

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

IPV(3)‐OPV vs IPV(2)‐OPV

Persons with faecal excretion after OPV challenge · preventing poliomyelitis

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

IPV‐OPV vs OPV

Vaccine‐associated paralytic polio (VAPP) cases (Range of · infants

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 participants
Low

IPV(3)‐OPV vs IPV(2)‐OPV

Vaccination coverage · preventing poliomyelitis

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

IPV(3)‐OPV vs IPV(2)‐OPV

Serious adverse events · preventing poliomyelitis

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

IPV‐OPV vs OPV

Neutralising antibodies with 2 IPV doses Geometric mean titres ( · infants

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 795 participants
Low

IPV‐OPV vs OPV

Persons with faecal polio excretion after OPV challenge (Range of · infants

IPV‐OPV showed no clear difference in persons with polio faecal excretion after OPV challenge (Range of compared with OPV (low certainty).

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
RR 2.24 [0.7, 7.12]
2 studies · 916 participants
Low

IPV‐OPV vs OPV

Vaccination coverage · infants

IPV‐OPV showed no clear difference in vaccination coverage ( compared with OPV (low certainty).

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
RR 1.01 [0.96, 1.06]
1 participants
Low

IPV‐OPV vs OPV

Serious adverse events (classified by MedDRA) (Range of · infants

IPV‐OPV showed no clear difference in serious adverse events (classified by MedDRA) (Range of compared with OPV (low certainty).

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
RR 0.88 [0.46, 1.7]
4 studies · 1948 participants
Low

IPV‐OPV vs IPV

Paralytic wild polio cases at 4 years (Change level from IPV‐OPV to IPV) · infants

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 participants
Very low

IPV‐OPV vs IPV

Vaccine‐associated paralytic polio (VAPP) cases (Range of · infants

1 finding from 1 review

Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention)

Pruritus · children with eczema

The review found no eligible studies for this question.

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cetirizine 10 mg/d vs placebo (4‐week intervention)

Secondary outcome: clinical flare · adults with eczema

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 84 participants
Low

Fexofenadine 120 mg/d vs placebo (1‐week intervention)

Pruritus · adults with eczema

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 400 participants
Moderate

Fexofenadine 120 mg/d vs placebo (1‐week intervention)

Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema

Fexofenadine 120 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (1‐week intervention) (moderate certainty).

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
RR 1.05 [0.74, 1.5]
1 study · 411 participants
Moderate

Fexofenadine 120 mg/d vs placebo (1‐week intervention)

Secondary outcome 1. Mean change in physician‐assessed clinical signs This outcome was assessed as investigator‐assessed change in the ratio of pruritus area to body surface area · adults with eczema

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Moderate

Fexofenadine 120 mg/d vs placebo (1‐week intervention)

Secondary outcome: quality of life · adults with eczema

The review found no eligible studies for this question.

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Fexofenadine 120 mg/d vs placebo (1‐week intervention)

Secondary outcome 3. Number of eczema flares, measured by, for example, ‘escalation of treatment’ or ‘use of topical anti‐inflammatory medications’ Amount of 0.1% hydrocortisone butyrate cream used during the study · adults with eczema

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Moderate

Loratadine 10 mg vs placebo (4‐week intervention)

Pruritus · adults with eczema

1 finding from 1 review

Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low